Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Fiocchi

Showing results (51-60 of 86) with videos related to

Pageof 9
Sort By:
Gastroenterology|September 1, 1986
Intestinal immunity and inflammation: recent progressC O Elson, M F Kagnoff, C Fiocchi, et al.
Gastroenterology|February 1, 1993
Immune activation genes in inflammatory bowel diseaseT Matsuura, G A West, K R Youngman, et al.
Gut|June 20, 2001
Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's diseaseJ Itoh, C de La Motte, S A Strong, et al.
The Journal of Surgical Research|January 1, 1992
Resident research award: tumor necrosis factor alpha selectively enhances growth and cytotoxic activity of tumor infiltrating lymphocytes from human colorectal cancerV M Stolfi, J W Milsom, J H Finke, et al.
Proceedings of the Association of American Physicians|January 1, 1996
Hypoproliferative human lamina propria T cells retain the capacity to secrete lymphokines when stimulated via CD2/CD28 pathwaysM Boirivant, I Fuss, C Fiocchi, et al.
Gastroenterology|April 1, 1984
Interleukin 2 activity of human intestinal mucosa mononuclear cells. Decreased levels in inflammatory bowel diseaseC Fiocchi, M L Hilfiker, K R Youngman, et al.
Digestive Diseases and Sciences|October 1, 1988
Interferon gamma production by human intestinal mucosal mononuclear cells. Decreased levels in inflammatory bowel diseaseB Y Lieberman, C Fiocchi, K R Youngman, et al.
The Journal of Surgical Research|April 1, 1988
Lymphokine-activated killer (LAK) cells from human intestinal mucosa: cytotoxic activity against tumor cell lines and modified self but not autologous and allogeneic colon cancer cellsJ L Trudel, K R Youngman, G A West, et al.
Gastroenterology|December 1, 1991
Loss of interleukin-2-producing intestinal CD4+ T cells in inflammatory bowel diseaseK Kusugami, T Matsuura, G A West, et al.
Journal of Veterinary Internal Medicine|July 9, 2011
An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogsS C Fiocchi, K A Selting, M P Rosenberg, et al.
Pageof 9

Showing results (51-60 of 86) with videos related to

Sort By:
Pageof 9
Gastroenterology|September 1, 1986
Intestinal immunity and inflammation: recent progressC O Elson, M F Kagnoff, C Fiocchi, et al.
Gastroenterology|February 1, 1993
Immune activation genes in inflammatory bowel diseaseT Matsuura, G A West, K R Youngman, et al.
Gut|June 20, 2001
Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's diseaseJ Itoh, C de La Motte, S A Strong, et al.
The Journal of Surgical Research|January 1, 1992
Resident research award: tumor necrosis factor alpha selectively enhances growth and cytotoxic activity of tumor infiltrating lymphocytes from human colorectal cancerV M Stolfi, J W Milsom, J H Finke, et al.
Proceedings of the Association of American Physicians|January 1, 1996
Hypoproliferative human lamina propria T cells retain the capacity to secrete lymphokines when stimulated via CD2/CD28 pathwaysM Boirivant, I Fuss, C Fiocchi, et al.
Gastroenterology|April 1, 1984
Interleukin 2 activity of human intestinal mucosa mononuclear cells. Decreased levels in inflammatory bowel diseaseC Fiocchi, M L Hilfiker, K R Youngman, et al.
Digestive Diseases and Sciences|October 1, 1988
Interferon gamma production by human intestinal mucosal mononuclear cells. Decreased levels in inflammatory bowel diseaseB Y Lieberman, C Fiocchi, K R Youngman, et al.
The Journal of Surgical Research|April 1, 1988
Lymphokine-activated killer (LAK) cells from human intestinal mucosa: cytotoxic activity against tumor cell lines and modified self but not autologous and allogeneic colon cancer cellsJ L Trudel, K R Youngman, G A West, et al.
Gastroenterology|December 1, 1991
Loss of interleukin-2-producing intestinal CD4+ T cells in inflammatory bowel diseaseK Kusugami, T Matsuura, G A West, et al.
Journal of Veterinary Internal Medicine|July 9, 2011
An open-label, dose-escalating phase I study of elsamitrucin (SPI 28090) in treatment of malignant solid tumors in dogsS C Fiocchi, K A Selting, M P Rosenberg, et al.
Pageof 9